This new article publication from Acta Pharmaceutica Sinica B, discusses how SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Nerandomilast significantly reduces the decline in forced vital capacity in adults with progressive pulmonary fibrosis over 52 weeks, thereby slowing the progression of the condition.

Panelists discuss that improving outcomes for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires multifaceted efforts including developing ...

Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood cells that defend the body by killing microbes, removing dead cells ...

Boehringer drug scores in another pulmonary fibrosis trial Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings.

Hundreds of people gathered in Pittsburgh’s Riverfront Park on Saturday for the Pulmonary Fibrosis Foundation’s annual walk.

Pulmonary Fibrosis: Scarring of the Lungs Pulmonary fibrosis, however, is a chronic and progressive lung condition where lung tissue becomes scarred or thickened.

In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...